Suspension aerosol formulations
View Patent ↗Pharmaceutical suspension aerosol formulations containing a therapeutically effective amount of a drug and HFC 134a, HFC 227, or a mixture thereof.
1. A pharmaceutical suspension aerosol formulation comprising:
(i) particulate drug;
(ii) 1,1,1,2,3,3,3-heptafluoropropane as propellant; and
(iii) ethanol in an amount of 5 to about 15 percent by weight, wherein the formulation contains no surfactant.
2. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is micronized.
3. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the drug is albuterol sulfate.
4. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the drug is pirbuterol acetate.
5. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is selected from the group consisting of formoterol, salmeterol, beclomethasone dipropionate, cromolyn, pirbuterol, albuterol, and pharmaceutically acceptable salts or solvates thereof.
6. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is formoterol or a pharmaceutically acceptable salt or solvate thereof.
7. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is salmeterol or a pharmaceutically acceptable salt or solvate thereof.
8. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is formoterol fumarate.
9. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is albuterol or a pharmaceutically acceptable salt or solvate thereof.
10. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is beclomethasone dipropionate a pharmaceutically acceptable solvate thereof.
11. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is formoterol or a pharmaceutically acceptable salt or solvate thereof.
12. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is cromolyn or a pharmaceutically acceptable salt or solvate thereof.
13. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is pirbuterol or a pharmaceutically acceptable salt or solvate thereof.
14. The pharmaceutical suspension aerosol formulation of claim 1 , wherein the particulate drug is disodium cromoglycate.